Concomitant Dosimetry During Radionuclide Peptide Therapy with 177-Lu-DOTA-tate and 177-Lu-Lanreotide

被引：0
|
作者：
Heute, D. R. [1 ]
Dobrozemsky, G. [1 ]
Traub, T. [1 ]
Warwitz, B. [1 ]
von Guggenberg, E. [1 ]
Gabriel, M. [1 ]
Virgolini, I. [1 ]
机构：
[1] Med Univ Innsbruck, A-6020 Innsbruck, Austria
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2005年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S202 / S202
页数：1
相关论文
共 50 条
  • [41] Dosimetry using Lu-177 DOTATATE, Lu-177 HA-DOTATATE and Lu-177 DOTATOC: Comparative Results in Patients Undergoing Peptide Receptor Radionuclide Therapy (PRRT)
    Schuchardt, C.
    Kulkarni, H. R.
    Wiessalla, S.
    Shahinfar, M.
    Shafaei, S.
    Kropf, S.
    Wester, H. J.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S224 - S225
  • [42] Assessment of Occupational Radiation Exposure During Administration of [177Lu]Lu-DOTA-TATE Using Active and Passive Dosimetry
    Riveira-Martin, M.
    Struelens, L.
    Iglesias, J. Munoz
    Schoonjans, W.
    Alonso, J. M. Nogueiras
    Tabuenca, O.
    Gomez, F. J. Salvador
    Medina, A. Lopez
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S226 - S227
  • [43] Personalized Incorporation Dosimetry for Lu-177-based Radionuclide Therapy
    Teske, F.
    Scholz, T.
    Bechler, U.
    Lincke, T.
    Sattler, B.
    Sabri, O.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S361 - S361
  • [44] Methodological Effects in Kidney Dosimetry in Lu-177 Radionuclide Therapy
    Heikkonen, J.
    Maenpaa, H.
    Tenhunen, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S265 - S265
  • [45] Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate
    Flavio Forrer
    Eric P. Krenning
    Peter P. Kooij
    Bert F. Bernard
    Mark Konijnenberg
    Willem H. Bakker
    Jaap J. M. Teunissen
    Marion de Jong
    Kirsten van Lom
    Wouter W. de Herder
    Dik J. Kwekkeboom
    European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36
  • [46] Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate
    Forrer, Flavio
    Krenning, Eric P.
    Kooij, Peter P.
    Bernard, Bert F.
    Konijnenberg, Mark
    Bakker, Willem H.
    Teunissen, Jaap J. M.
    de Jong, Marion
    van Lom, Kirsten
    de Herder, Wouter W.
    Kwekkeboom, Dik J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 (07) : 1138 - 1146
  • [47] Peptide Receptor Radionuclide Therapy using SSTR antagonists: biokinetics and dosimetry of Lu-177 DOTA-LM3
    Schuchardt, C.
    Wiessalla, S.
    Singh, A.
    Zhang, J.
    Kulkarni, H. R.
    Mueller, D.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S90 - S90
  • [48] Lu-177 DOTA-TATE for peptide receptor radionuclide therapy (PRRT): organ-, tumor- and blood kinetics
    Wehrmann, C.
    Senftleben, S.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S338 - S339
  • [49] Personalized, dosimetry-based PRRT therapy in patients with neuroendocrine tumors using [177Lu]Lu-DOTA-TATE or [177Lu]Lu/[90Y]Y-DOTA-TATE mixture - the initial results of DUONEN multicenter study
    Opalinska, M.
    Kaminski, G.
    Dedecjus, M.
    Kowalska, A.
    Kolodziej, M.
    Saracyn, M.
    Gasior-Perczak, D.
    Lenda-Tracz, W.
    Sowa-Staszczak, A.
    Borkowska, A.
    Budzynska, A.
    Kubik, A.
    Chalewska, W.
    Kacperski, K.
    Szubstarska, P.
    Garnuszek, P.
    Mikolajczak, R.
    Hubalewska-Dydejczyk, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S314 - S314
  • [50] 177Lu-DOTA-lanreotide:: A novel tracer as a targeted agent for tumor therapy
    Banerjee, S
    Das, T
    Chakraborty, S
    Samuel, G
    Korde, A
    Srivastava, S
    Venkatesh, M
    Pillai, MRA
    NUCLEAR MEDICINE AND BIOLOGY, 2004, 31 (06) : 753 - 759
12345